Citadel Advisors’s Ovid Therapeutics OVID Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2026
Q2 | – | Sell |
-367,902
| Closed | -$949K | – | 14541 |
|
|
2026
Q1 | $817K | Sell |
367,902
-429,922
| -54% | -$769K | ﹤0.01% | 8136 |
|
|
2025
Q4 | $1.3M | Buy |
797,824
+392,442
| +97% | +$604K | ﹤0.01% | 6833 |
|
|
2025
Q3 | $527K | Buy |
+405,382
| New | +$351K | ﹤0.01% | 9011 |
|
|
2025
Q2 | – | Sell |
-367,974
| Closed | -$111K | – | 14373 |
|
|
2025
Q1 | $115K | Buy |
367,974
+360,517
| +4,835% | +$222K | ﹤0.01% | 11266 |
|
|
2024
Q4 | $6.96K | Buy |
+7,457
| New | +$8.34K | ﹤0.01% | 13770 |
|
|
2024
Q2 | – | Sell |
-147,339
| Closed | -$410K | – | 15075 |
|
|
2024
Q1 | $449K | Buy |
147,339
+136,137
| +1,215% | +$456K | ﹤0.01% | 8621 |
|
|
2023
Q4 | $36.1K | Buy |
+11,202
| New | +$38.3K | ﹤0.01% | 12105 |
|
|
2023
Q3 | – | Sell |
-30,812
| Closed | -$101K | – | 14868 |
|
|
2023
Q2 | $101K | Sell |
30,812
-27,025
| -47% | -$91.8K | ﹤0.01% | 10920 |
|
|
2023
Q1 | $149K | Buy |
57,837
+19,809
| +52% | +$46.9K | ﹤0.01% | 10647 |
|
|
2022
Q4 | $70.7K | Buy |
+38,028
| New | +$64.8K | ﹤0.01% | 11689 |
|
|
2022
Q2 | – | Sell |
-38,265
| Closed | -$92.5K | – | 13770 |
|
|
2022
Q1 | $120K | Sell |
38,265
-40,160
| -51% | -$126K | ﹤0.01% | 12087 |
|
|
2021
Q4 | $252K | Sell |
78,425
-18,599
| -19% | -$63.7K | ﹤0.01% | 11334 |
|
|
2021
Q3 | $326K | Buy |
97,024
+60,911
| +169% | +$222K | ﹤0.01% | 10886 |
|
|
2021
Q2 | $141K | Sell |
36,113
-45,655
| -56% | -$180K | ﹤0.01% | 12559 |
|
|
2021
Q1 | $329K | Buy |
81,768
+3,963
| +5% | +$13.2K | ﹤0.01% | 10624 |
|
|
2020
Q4 | $180K | Sell |
77,805
-23,005
| -23% | -$107K | ﹤0.01% | 9818 |
|
|
2020
Q3 | $579K | Buy |
100,810
+78,730
| +357% | +$527K | ﹤0.01% | 7029 |
|
|
2020
Q2 | $163K | Buy |
+22,080
| New | +$103K | ﹤0.01% | 8682 |
|
|
2020
Q1 | – | Sell |
-38,088
| Closed | -$158K | – | 10001 |
|
|
2019
Q4 | $158K | Buy |
+38,088
| New | +$120K | ﹤0.01% | 8333 |
|
|
2018
Q4 | – | Sell |
-14,537
| Closed | -$82K | – | 9592 |
|
|
2018
Q3 | $82K | Buy |
+14,537
| New | +$110K | ﹤0.01% | 8651 |
|
|
2017
Q3 | – | Sell |
-19,493
| Closed | -$204K | – | 7884 |
|
|
2017
Q2 | $204K | Buy |
+19,493
| New | +$255K | ﹤0.01% | 6544 |
|
Other funds holding OVID
JT
EAM
RCM
AAA
ACM
Citadel Advisors's OVID Position: Q2 2026 in Review
Citadel Advisors sold out of Ovid Therapeutics (OVID) in Q2 2026, closing a stake of 367,902 shares — an estimated $949K sold.
Citadel Advisors first reported a position in OVID in Q2 2017 and held it in 21 quarters. The position peaked at $1.3M in Q4 2025. 130 funds tracked by Wall St. Rank hold OVID as of Q2 2026.
- Citadel Advisors reported no remaining Ovid Therapeutics position as of Q2 2026 after selling out during the quarter.
- Citadel Advisors sold 367,902 Ovid Therapeutics shares in Q2 2026, an estimated $949K.
- Citadel Advisors first reported a position in Ovid Therapeutics in Q2 2017 and held it in 21 quarters.
- Citadel Advisors's Ovid Therapeutics position peaked at $1.3M in Q4 2025.
- 130 funds tracked by Wall St. Rank held Ovid Therapeutics as of Q2 2026.
Based on Citadel Advisors's 13F filing for Q2 2026, filed 14 Aug 2026.